[1]SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease[J].Trends in Endocrinology and Metabolism

[2]Svetlana V Michurina,Irina Ju Ishenko,Vadim V Klimontov,Sergey A Archipov,Natalia E Myakina,Marina A Cherepanova,Eugenii L Zavjalov,Galina V Koncevaya,Vladimir I Konenkov.Linagliptin alleviates fatty liver disease in diabetic db/db mice[J].World journal of diabetes,2016,7(19):534-546.

[3]K. Fosgerau,L. Jessen,J. Lind Tolborg,T. Østerlund,K. Schæffer Larsen,K. Rolsted,M. Brorson,J. Jelsing,T. Skovlund Ryge Neerup.The novel GLP‐1‐gastrin dual agonist,ZP3022, increases β‐cell mass and prevents diabetes in db/db mice[J].Diabetes, obesity & metabolism,2013,15(1):62-71.

[4]Rachel Charlotte Moffett,Steven Patterson,Nigel Irwin,Peter R. Flatt.Positive effects of GLP‐1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes[J].Diabetes/metabolism research and reviews,2015,31(3):248-255.

[5]DU Chongjin,ZHANG Xiaohui,KONG Shuo,LI Siyuan,QI Li.From non-alcoholic fatty liver disease to metabolic associated fatty liver disease[J].Anhui Medical and Pharmaceutical Journal,2024,28(5):1039-1043.

[6]LI Chunjun,YU Demin.Update study of GLP-1 receptor agonist in the treatment of non-alcoholic fatty liver disease[J].Tianjin Medical Journal,2015,43(11):1230-1234.

[7]LI N,LIU Ji,WANG Guang,XIE Guomin,QU Aijuan,LI Hongmei.Update on glucagon-like peptide-1 receptor agonists in metabolic associated fatty liver disease[J].Chinese Journal of Arteriosclerosis,2021,29(5):446-450.

[8]Stephania Guzman,Magdalena Dragan,Hyokjoon Kwon,Vanessa de Oliveira,Shivani Rao,Vrushank Bhatt,Katarzyna M. Kalemba,Ankit Shah,Vinod K. Rustgi,He Wang,Paul R. Bech,Ali Abbara,Chioma Izzi-Engbeaya,Pinelopi Manousou,Jessie Y. Guo,Grace L. Guo,Sally Radovick,Waljit S. Dhillo,Fredric E. Wondisford,Andy V. Babwah,Moshmi Bhattacharya.Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model[J].The Journal of clinical investigation,2022,132(10).

[9]Jawaher Alharthi,Olivier Latchoumanin,Jacob George,Mohammed Eslam.Macrophages in metabolic associated fatty liver disease[J].World journal of gastroenterology : WJG,2020,26(16):1861-1878.

[10]Liu Haoming,Yu Suguo.Liraglutide in treatment of type 2 diabetes mellitus complicated with metabolic associated fatty liver disease[J].International Medicine & Health Guidance News,2022,28(19):2806-2809.

[11]Cha Dae Ryong,Zhang Xiaoyan,Zhang Yahua,Wu Jing,Su Dongming,Han Jee Young,Fang Xuefen,Yu Bo,Breyer Matthew D,Guan Youfei.Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice[J].Diabetes,2007,56(8):2036-2045.

[12]Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice[J].The Journal of nutritional biochemistry

[13]Mujdat Zeybel,Ozlem Altay,Muhammad Arif,Xiangyu Li,Hong Yang,Claudia Fredolini,Murat Akyildiz,Burcin Saglam,Mehmet Gokhan Gonenli,Dilek Ural,Woonghee Kim,Jochen M Schwenk,Cheng Zhang,Saeed Shoaie,Jens Nielsen,Mathias Uhln,Jan Born,Adil Mardinoglu.Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients[J].Molecular systems biology,2021,17(10).

[14]YanXia Sang,TianHong Zhou,HongJian Li,YanHong Ran,DeQi Jiang,Fei Zheng,Ying Chen,CongFeng Wang,Xin Zou.A new long-acting GLP-1 derivative KTP ameliorates hyperglycemia and dyslipidemia and improves pancreas and fatty liver in db/db mice[J].Chinese science bulletin,2013,58(20):2447-2453.

[15]Liang Yin,Osborne Melville C,Monia Brett P,Bhanot Sanjay,Gaarde William A,Reed Chantal,She Pengxiang,Jetton Thomas L,Demarest Keith T.Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice[J].Diabetes,2004,53(2):410-417.

[16]Zhang,Hanlin,Dong,Meng,Yuan,Shouli,Jin,Wanzhu.Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice[J].Biotechnology letters,2022,44(10):1149-1162.

[17]Bingning Dong,Pradip K. Saha,Wendong Huang,Wenling Chen,Lutfi A. Abu-Elheiga,Salih J. Wakil,Robert D. Stevens,Olga Ilkayeva,Christopher B. Newgard,Lawrence Chan,David D. Moore.Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease[J].Proceedings of the National Academy of Sciences of the United States of America,2009,106(44):18831-18836.

[18]Park Cheol Whee,Kim Hyeong Wook,Ko Seung Hyun,Lim Ji Hee,Ryu Gyeong Ryul,Chung Hyun Wha,Han Sang Woo,Shin Seog Jun,Bang Byung Kee,Breyer Matthew D,Chang Yoon Sik.Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice[J].Journal of the American Society of Nephrology : JASN,2007,18(4):1227-1238.

[19]Haque Mahmadul,Sanyal Arun J.The metabolic abnormalities associated with non-alcoholic fatty liver disease[J].Best Practice & Research: Clinical Gastroenterology,2002,16(5):709-731.

[20]Tirzepatide: A novel,first-in-class,dual GIP/GLP-1 receptor agonist[J].Journal of diabetes and its complications